Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 7

1.

Rosiglitazone and the need for a new drug safety agency.

Garattini S, Bertele' V.

BMJ. 2010 Oct 6;341:c5506. doi: 10.1136/bmj.c5506. No abstract available.

PMID:
20926483
[PubMed - indexed for MEDLINE]
2.

Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality.

Nissen SE, Wolski K.

Arch Intern Med. 2010 Jul 26;170(14):1191-1201. doi: 10.1001/archinternmed.2010.207. Review.

PMID:
20656674
[PubMed - indexed for MEDLINE]
3.

The truth about rosiglitazone (avandia).

Ledbetter C, Laustsen G.

Nurse Pract. 2008 Jun;33(6):10-1. Review. No abstract available.

PMID:
18528195
[PubMed - indexed for MEDLINE]
4.

Rosiglitazone and cardiovascular risk.

Kaul S, Diamond GA.

Curr Atheroscler Rep. 2008 Oct;10(5):398-404. Review.

PMID:
18706281
[PubMed - indexed for MEDLINE]
5.

The safety of rosiglitazone in the treatment of type 2 diabetes.

Singh S, Loke YK.

Expert Opin Drug Saf. 2008 Sep;7(5):579-85. doi: 10.1517/14740338.7.5.579 . Review.

PMID:
18759710
[PubMed - indexed for MEDLINE]
6.

Hepatotoxicity of thiazolidinediones.

Isley WL.

Expert Opin Drug Saf. 2003 Nov;2(6):581-6. Review.

PMID:
14585066
[PubMed - indexed for MEDLINE]
7.

The cardiovascular safety of rosiglitazone.

Ajjan RA, Grant PJ.

Expert Opin Drug Saf. 2008 Jul;7(4):367-76. doi: 10.1517/14740338.7.4.367 . Review.

PMID:
18613801
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk